Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 3:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 193 matching trials from the live ClinicalTrials.gov search.
Completed Phase 1 Interventional

Pancreatic Clamp in NAFLD

NCT05724134
Conditions
Insulin Resistance, Prediabetic State, Hyperinsulinemia, Non-Alcoholic Fatty Liver Disease, Obesity
Interventions
Insulin human, Octreotide Acetate, Glucagon, Growth Hormone, Human, [6,6-2H2] D-glucose, 20% D-glucose (aq), BOOST Plus, CORE Bar, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Completed Phase 1 Interventional Accepts healthy volunteers

Mechanisms of Cerebrovascular Control

NCT02936687
Conditions
Metabolic Syndrome X
Interventions
NOS Inhibition, ET-1 Inhibition, NOS Inhibition Placebo, 3 Tesla MRI, Intravenous Catheter, Oral Glucose Tolerance Test, ET-1 Inhibition Placebo
Drug · Device · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 45 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Brain Neoplasms, Intracranial Aneurysm
Interventions
Insulin
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Type 1 Diabetes Mellitus
Interventions
AID System, Insulin Lispro
Device · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Renton, Washington
Completed Not applicable Interventional Results available

Two Way Crossover Closed Loop Study MPC vs FMPD

NCT04771403
Conditions
Type 1 Diabetes
Interventions
FMPD AP algorithm, MPC AP system, Dexcom G6 Continuous Glucose Monitoring (CGM) System
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Insulin Modulation of fMRI Connectivity in Healthy Adults

NCT02982551
Conditions
Healthy Volunteers
Interventions
Insulin, Taste Task, Magnetic Resonance Imaging, Dextrose
Drug · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years to 30 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Diabetes Mellitus Type 1
Interventions
iPhone bionic pancreas, iLet bionic pancreas, Xeris Xerisol glucagon, Lilly glucagon, iLet infusion set, Contact Detach infusion set
Device · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Terminated Not applicable Interventional Results available

Two Bag System for Diabetic Ketoacidosis

NCT03660189
Conditions
Diabetic Ketoacidosis
Interventions
Two bag system
Other
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Liver Glycogen and Hypoglycemia in Humans

NCT03241706
Conditions
Hypoglycemia; Iatrogenic
Interventions
Low Fructose, Saline, Somatostatin, Insulin, Glucagon, Dextrose solution, High Fructose
Drug
Lead sponsor
Jason Winnick
Other
Eligibility
21 Years to 40 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Diabetic Ketoacidosis, Type 1 Diabetes, Type 2 Diabetes
Interventions
Early Glargine, Late Glargine, IV insulin infusion, IV fluid and electrolytes replacement
Drug · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Diabetes, Hypoglycemia
Interventions
hyperinsulinemic-hypoglycemic clamp, 13C-MRS procedure/Acetate infusion
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 40 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Role of TLR4 on Lipid-induced Insulin Resistance

NCT02321111
Conditions
Insulin Sensitivity
Interventions
Eritoran, D5W (5% Dextrose in water)
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Recruiting Phase 1 Interventional Accepts healthy volunteers

Graded Insulin Suppression Test P&F

NCT06592261
Conditions
Insulin Resistance, Hyperinsulinemia, Obesity, Healthy
Interventions
Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia), Insulin regular, 32 mU/m2/min (hyperinsulinemia), Octreotide Acetate, 6-45 ng/kg/min, Dextrose 20 % in Water, Glucagon, 0-0.5 ng/kg/min
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Not listed Not applicable Interventional Accepts healthy volunteers

Ghrelin Effect on Beta Cell Function in Health and Disease

NCT01729299
Conditions
Diabetes
Interventions
Exendin (9-39), acyl ghrelin, saline
Drug
Lead sponsor
David Dalessio
Other
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Cincinnati, Ohio
Completed Phase 1 Interventional Accepts healthy volunteers

Molar Potency Study of HM12470 in Healthy Subjects

NCT03330327
Conditions
Healthy Subjects
Interventions
HM12470
Biological
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chula Vista, California
Conditions
Evidence of Liver Transplantation, Hyperglycemia, Rejection
Interventions
Insulin
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Recruiting Not applicable Interventional

Closed Loop Context Aware AID

NCT06676657
Conditions
Type 1 Diabetes
Interventions
iPancreas automated insulin delivery system
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Recruiting Phase 1 Interventional Accepts healthy volunteers

Alpelisib Challenge Test (ACT)

NCT07778524
Conditions
Insulin Resistance, Type 2 Diabetes, Obesity & Overweight, Healthy Adult Participants
Interventions
Alpelisib 300 mg, Alpelisib Challenge Test (ACT): Mixed Meal Tolerance Test (MMTT) after taking alpelisib, Hyperglycemic clamp
Drug · Diagnostic Test
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Conditions
Type 1 Diabetes Mellitus
Interventions
AID System, Insulin Lispro
Device · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Renton, Washington
Conditions
Type 1 Diabetes Mellitus
Interventions
Investigational inhaled insulin (Technosphere), Artificial Pancreas (AP) device (APS©)
Drug · Device
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
21 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Santa Barbara, California
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
Faster-acting insulin aspart, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Completed Phase 1 Interventional Accepts healthy volunteers

Molar Potency Study of HM12460A in Healthy Subjects

NCT03330314
Conditions
Healthy Volunteers
Interventions
HM12460A
Biological
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 60 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chula Vista, California
Conditions
Diabetes
Interventions
Hyperinsulinemic-hypoglycemic clamp
Procedure
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 40 Years
Enrollment
4 participants
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Conditions
Infant, Low Birth Weight, Hyperglycemia
Interventions
alanine, amino acids, glucagon, glucose, glutamine, glycerol, insulin, leucine, lipids, urea
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
4 Days to 6 Days
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Houston, Texas